Gene and cell therapies in China: booming landscape under dual-track regulation.

Yin, Chen; Gao, Jianchao; Li, Guanqiao; Hu, Hongxi; Zhou, Liyun; Lu, Shuang; Chen, Xiaoyuan

Yin, Chen; Gao, Jianchao; Li, Guanqiao; Hu, Hongxi; Zhou, Liyun; Lu, Shuang; Chen, Xiaoyuan.

Affiliation

Yin C; Tsinghua Clinical Research Institute, School of Medicine, Tsinghua University, Beijing, China.
Gao J; National Center for Drug Evaluation, National Medical Products Administration, Beijing, China.
Li G; Vanke School of Public Health, Tsinghua University, Beijing, China.
Hu H; Pharmcube (Beijing) Co., Ltd., Beijing, China.
Zhou L; Pharmcube (Beijing) Co., Ltd., Beijing, China.
Lu S; National Center for Drug Evaluation, National Medical Products Administration, Beijing, China. lush@cde.org.cn.
Chen X; Tsinghua Clinical Research Institute, School of Medicine, Tsinghua University, Beijing, China. cxya02648@tsinghua.edu.cn.

J Hematol Oncol ; 15(1): 139, 2022 10 05.

Article in En | MEDLINE | ID: mdl-36199142

Subject(s)

Neoplasms; Receptors, Chimeric Antigen; Cell- and Tissue-Based Therapy; Drugs, Investigational; Genetic Therapy; Humans; Neoplasms/genetics; Neoplasms/therapy; Receptors, Chimeric Antigen/genetics

Key words

Clinical development; Dual-track regulation; GCT

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Receptors, Chimeric Antigen / Neoplasms Type of study: Guideline Limits: Humans Language: En Journal: J Hematol Oncol Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 2022 Document type: Article Affiliation country: China Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google